THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

Bente Glintborg ,Anne Loft ,Natalia Manilo ,Asta Linauskas ,Frank Mehnert ,Lars Peter Holst Andersen ,E B Dalsgaard ,Jakob Espesen ,Hanne Lindegaard ,Birgitte Lange Andersen ,Susanne Højmark Jakobsen ,Dorte Dalsgaard Pedersen ,Inger Marie Jensen Hansen ,Dorte Vendelbo Jensen ,Salome Kristensen ,Stavros Chrysidis ,Kamilla Danebod ,Ns Krogh ,Jolanta Grydehøj ,Henrik Nordin ,Inge Juul Sørensen ,Oliver Hendricks ,Johnny Lillelund Raun ,Emina Omerovic ,Merete Lund Hetland

doi:10.1136/annrheumdis-2018-eular.2113

THU0189 One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

Bente Glintborg , Anne Loft + Show 23 more

Open Access

https://doi.org/10.1136/annrheumdis-2018-eular.2113

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2018

#Etanercept #DANBIO Registry + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundIn Denmark, rheumatoid arthritis(RA), psoriatic arthritis(PsA) and axial spondyloarthritis(AxSpA) patients (pts) treated with originator etanercept (ETA) 50 mg SC conducted a mandatory non-medical switch to biosimilar Etanercept (SB4) in April...

Full Text